Clinical Trial: Safety of MOON101 for the Treatment of Peanut Allergy

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07580898) titled 'Safety of MOON101 for the Treatment of Peanut Allergy' on April 24.

Brief Summary: The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is:

1. the incidence and frequency of all treatment emergent adverse events (TEAEs) from baseline through study exit.

2. to determine the highest tolerated dose for each participant, as defined by the highest MOON101 dose level administered which did not cause a dose-limiting symptom (DLS).

The study will compare MOON101 and placebo. All partici...